Bosakitug

DB19101InvestigationalProtein Based Therapies

Bosakitug (BSI-045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and BSI-045B Add-on Therapy With Dupilumab in Atopic Dermatitis).

Mechanism: Pharmacologically active on Thymic stromal lymphopoietin
Curator reviewed
Code names: ATI-045 · BSI-045B

Resolves to

Compound

UNII5T953J9HZNCAS2762183-23-1

Targets

Q969D9TSLP

What you can answer from here — as of November 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Bosakitug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account